Back

Go back

What products will remain within Pfizer PAP as of January 1, 2026?

Question

Answer

Type	Primary Care	Specialty Care	Oncology
Medicines	Celontin Depo-Estradiol Duavee Estring Norpace CR Nurtec Premarin Premphase Prempro Tikosyn Zarontin Zavzpret	BeneFIX Cibinqo Elelyso Eucrisa Litfulo Somavert Velsipity Vyndamax Xeljanz (no new patients starting July 1, 2026) Xyntha	Besponsa Bosulif (no new patients starting July 1, 2026) Braftovi Daurismo Ibrance Inlyta Lorbrena Mektovi Mylotarg Talzenna Xalkori
Vaccines	Abrysvo Comirnaty Penbraya Prevnar 20 Trumenba

NOTE: This list of products is subject to change

updates

19